BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr 348 phosphorylation

In conclusion, our data support the idea that BIN1 modulates the AD risk through an intrica te regulation of its interaction with Tau. Alteration in BIN1 expression or activity may disrupt this regulatory balance with Tau and have direct effects on learning and memory.
Source: Acta Neuropathologica - Category: Neurology Source Type: research

Related Links:

Caring for someone with Alzheimer's disease can be both challenging and rewarding. Learn about tips to make it easier, as well as when to seek professional help.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
However, no link seen between migraines and vascular dementia
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Neurology, Psychiatry, Geriatrics, Journal, Source Type: news
Researchers at private Arizona-based firm NeuroEM Therapeutics tested their transcranial electromagnetic treatment (TEMT) on a group of eight patients with mild or moderate Alzheimer's.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN00751B, PaperArthur Viode, Stephane Epelbaum, Imen Benyounes, Marc Verny, Bruno Dubois, Christophe Junot, francois Fenaille, Foudil Lamari, Francois Becher Tau and α-synuclein are central in several neurodegenerative diseases, including Alzheimer Disease (AD), Dementia with Lewy bodies (DLB) and Parkinson disease (PD). New analytical methods for precise quantification of cerebrospinal... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Conditions:   Blood Brain Barrier;   Alzheimer Disease;   Cognitive Dysfunction;   Dementia Intervention:   Diagnostic Test: Contrast agent enhanced MRI using Gadovist Sponsors:   Charite University, Berlin, Germany;   Prof. Dr. med. Jochen Fiebach (Senior Physician) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Alzheimer Disease Interventions:   Dietary Supplement: Wismemo;   Dietary Supplement: Placebo Sponsors:   GenMont Biotech Incorporation;   Chang Gung Memorial Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
WEDNESDAY, Sept. 18, 2019 -- Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia, according to a study published online Sept. 4 in the International Journal of Geriatric Psychiatry. Rebecca E. Morton, from...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
This Viewpoint describes setbacks in trials of disease-modifying therapies for Alzheimer disease and describes options for future research and clinical care.
Source: JAMA Psychiatry - Category: Psychiatry Source Type: research
ConclusionsWe examined the usefulness of voxel-based statistical analysis for amyloid PET. This method provides objectiveZ-score maps andZ-sum values, which were observed to be helpful as an adjunct to visual interpretation especially for cases with mild or limited A β accumulation. This approach could improve the Aβ detection sensitivity, reduce inter-reader variability, and allow for detailed monitoring of Aβ deposition.Trial registrationThe number of the J-ADNI study isUMIN000001374
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Alzheimer's | Brain | Genetics | Learning | Neurology | Universities & Medical Training